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Abstract
Background: The blood-brain barrier (BBB) dysfunction represents an early feature of Alzheimer’s disease (AD) that
precedes the hallmarks of amyloid beta (amyloid β) plaque deposition and neuronal neurofibrillary tangle (NFT)
formation. A damaged BBB correlates directly with neuroinflammation involving microglial activation and reactive
astrogliosis, which is associated with increased expression and/or release of high-mobility group box protein 1
(HMGB1) and thrombin. However, the link between the presence of these molecules, BBB damage, and progression to
neurodegeneration in AD is still elusive. Therefore, we aimed to profile and validate non-invasive clinical biomarkers of
BBB dysfunction and neuroinflammation to assess the progression to neurodegeneration in mild cognitive impairment
(MCI) and AD patients.
Methods: We determined the serum levels of various proinflammatory damage-associated molecules in aged control
subjects and patients with MCI or AD using validated ELISA kits. We then assessed the specific and direct effects of
such molecules on BBB integrity in vitro using human primary brain microvascular endothelial cells or a cell line.
Results: We observed a significant increase in serum HMGB1 and soluble receptor for advanced glycation end
products (sRAGE) that correlated well with amyloid beta levels in AD patients (vs. control subjects). Interestingly, serum
HMGB1 levels were significantly elevated in MCI patients compared to controls or AD patients. In addition, as a marker
of BBB damage, soluble thrombomodulin (sTM) antigen, and activity were significantly (and distinctly) increased in MCI
and AD patients. Direct in vitro BBB integrity assessment further revealed a significant and concentration-dependent
increase in paracellular permeability to dextrans by HMGB1 or α-thrombin, possibly through disruption of zona
occludins-1 bands. Pre-treatment with anti-HMGB1 monoclonal antibody blocked HMGB1 effects and leaving BBB
integrity intact.
Conclusions: Our current studies indicate that thrombin and HMGB1 are causal proximate proinflammatory mediators
of BBB dysfunction, while sTM levels may indicate BBB endothelial damage; HMGB1 and sRAGE might serve as clinical
biomarkers for progression and/or therapeutic efficacy along the AD spectrum.
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Background
Despite overarching evidence, the amyloid hypothesis
in Alzheimer’s disease (AD) first elaborated in 1991,
has yet to provide positive outcomes notwithstanding
the billions spent on clinical trials [1]. The neuropatho-
logical hallmarks of AD are extracellular amyloid beta
(Aβ)/neuritic plaques and intracellular neurofibrillary
tangle (NFT) formation [2]. In association with these
hallmarks, soluble Aβ levels increase in the blood, both
in AD patients and transgenic mouse models [3–5],
while the brain amyloid β aggregates promote a neu-
roinflammatory response mediated by activated micro-
glia, astrocytes, and microvascular endothelial cells
(ECs) [6, 7]. Since late-onset AD (LOAD) is not associ-
ated with such manifestations information from AD,
transgenic animal models cannot be fully extrapolated
to human AD pathology. Furthermore, microglial acti-
vation and other aspects of neuroinflammation involv-
ing oxidative stress (reactive oxygen species (ROS),
nitric oxide (NO)) actually precede neuronal damage
[8, 9], prior to AD histopathologic lesions. Moreover, a
critical characteristic of neuroinflammation is the dis-
ruption of the blood-brain barrier (BBB) that extends
beyond the tissue or cellular pathophysiology of endo-
thelial cell (EC) dysfunction to the neurovascular unit
(NVU), including astrocytic end-feet, microglia, neu-
rons, and pericytes [10–12]. Recent National Institutes
of Health (NIH) workshops have emphasized key areas
that must be focused on as it relates to AD neuroin-
flammation research involving the BBB: (1) transport of
Aβ and other macromolecules in and out of the brain,
i.e., permeability; (2) BBB as both the source and target
of inflammatory factors; and (3) effects of oxidative
stress, ROS, and NO on BBB. Besides astrogliosis, acti-
vation and transmigration of blood-borne substances
and circulating immune cells into the CNS is a less stud-
ied and underappreciated area in AD research [13–16].
The precise molecular factors governing the initial BBB
damage leading to neurodegeneration, in general, and AD,
in particular, are not well understood.
Thrombin and high-mobility group box protein 1
(HMGB1) are key molecules of two most potent host
defense systems that converge on the innate immune
system, coagulation, and inflammation. We postulated
that they may play significant roles in the BBB disruption
since both are proinflammatory and both are known to
disrupt vascular barriers in other tissues [17–20]. Throm-
bin is a proinflammatory serine protease that is well
known for its essential role as the ultimate protease in the
coagulation pathway. HMGB1 is a non-histone nuclear
protein with dual functions depending on localization.
Within the cells, it is localized primarily to the nucleus
where it binds DNA and plays a role in transcriptional
regulation [21]. However, extracellular HMGB1 serves as
a proinflammatory cytokine and is a late mediator of
sepsis [22]. Beyond infections, HMGB1 has pathogenic
roles during trauma and sterile inflammation, such as
systemic inflammatory response syndrome (SIRS), where
elevated levels in sera orchestrate key events including
leukocyte recruitment and white blood cell (WBC) induc-
tion to secrete inflammatory cytokines [23, 24].
Relevant to our studies, HMGB1 impairs memory
behavior in mice that is mediated via Toll-like receptor 4
(TLR4) and the receptor for advanced end product gly-
cation (RAGE) [25]. These pre-clinical data correlate
with clinical studies showing that sepsis survivors have
permanent cognitive deficits [26] and that these may
also be mediated via HMGB1, but the precise mechan-
ism remains unknown. HMGB1 and another alarmin,
S100B, along with Aβ, are now considered as three sig-
nificant damage or danger-associated molecular patterns
(DAMPs) that “fan the flame” [27] of neuroinflammation
in AD [28]. How they might do this is currently unknown.
As an approach to this problem, we first measured levels
of these DAMPs in mild cognitive impairment (MCI), AD,
and normal aged subjects and then used pure proteins in
the range of these levels to perturb human BBB function
in vitro.
Methods
Human subjects and specimen collection
The human study was approved by the institutional
review board at the University of Kansas Medical Center
(KUMC) and was performed in compliance with the
Helsinki Declaration. All subjects were recruited from
the KU Alzheimer Disease Center (ADC) following a
written informed consent, and all demographic informa-
tion was de-identified. Subjects in the AD, MCI, and
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aged control cohorts met the criteria as outlined in the
2011–2012 NIA/Alzheimer’s Association Guidelines for
AD by McKhann et al. [29] and for MCI by Albert et al.
[30]. Furthermore, all subjects were screened by clinical
dementia rating (CDR) and neuropsychological testing
as defined by the Uniform Data Set of the Alzheimer
Disease Centers and underwent a consensus review.
MCI patients were further classified as “MCI due to AD”
if another more likely cause was not identified. Our MCI
cohort patients were all designated MCI due to AD.
Venous blood collection was performed with BD
Vaccutainer® blood collection tubes and centrifuged. The
serum samples were aliquoted and stored at −80 °C until
analysis. Demographic information for these patient
groups is shown in Table 1.
Cell culture
The human cerebromicrovascular endothelial cell line
(hCMEC/D3) was a gift from Dr. P.O. Couraud
(INSERM, France). This cell line has been widely used
as a representative model of human BBB in vitro for
mechanistic studies involving the molecular regulation
of BBB integrity [31]. Cells between passages 28 and 31
were cultured in HEPES-buffered EBM-2 media supple-
mented with growth factors and antibiotics and main-
tained at 37 °C with 5 % CO2 exposure. In preliminary
experiments, primary human brain microvascular endo-
thelial cells (HBMEC) were cultured in Dr. KY Kim’s
laboratory (KUMC) as described previously [32].
Analysis of serum biomarkers
Human serum samples were thawed on ice and analyzed
by enzyme-linked immunosorbent assay (ELISA) for
quantification of HMGB1 (Novatein Biosciences, Woburn,
MA), s100β (EMD Millipore, Billerica, MA), amyloid β
(aa 1-42), and soluble receptor for advanced glycation
end products (sRAGE) from R&D Systems (Minneapolis,
MN, USA), according to the manufacturers’ instructions.
Soluble thrombomodulin (sTM) antigen (TMa) levels
were assayed by kit (Stago, Gennevilliers, France), and
sTM activity was measured as described previously [33].
BBB integrity assessment
Cells were seeded on Corning Transwell® polyester
membrane inserts (12-well, 0.4 μm pore size) as previ-
ously described [31]. Monolayer integrity and morph-
ology were periodically assessed by transendothelial
electrical resistance (TEER; Ω cm2) and phase contrast
microscopy, respectively. Cells were maintained in treat-
ment media (EMB-2 supplemented with 10 mM HEPES,
antibiotics, and 1 % human serum) overnight prior to
treatment with human recombinant HMGB1 protein
(rHMGB1) with endotoxin levels lower than 0.1 EU per
microgram of the protein (R&D Systems, Minneapolis,
MN, USA). Following 3 h of treatment with rHMGB1
(5, 10, and 50 ng/mL), α-thrombin (0.5, 1, and 5 nM) or
control media, inserts were transferred to new 12-well
plates and transport buffer added (pre-warmed HBSS
buffer with antibiotics and 0.5 % BSA) to the apical
(500 μL) and basal compartment (1000 μL). After incu-
bation for 20 min at 37 °C under 5 % CO2 exposure, a
Table 1 Human subject demographics (gender and age were
shown for each subject in AD, MCI, and control cohorts at the
time of blood collection)
Patient ID Gender Age at draw Dx at draw
1 F 80 AD
2 F 77 AD
3 F 81 AD
4 F 60 AD
5 M 63 AD
6 M 76 AD
7 M 73 AD
8 M 81 AD
9 M 67 AD
10 M 70 AD
11 M 84 AD
12 M 88 AD
1 F 67 MCI
2 M 88 MCI
3 M 76 MCI
4 M 74 MCI
5 M 77 MCI
6 M 64 MCI
7 M 72 MCI
8 M 84 MCI
9 M 68 MCI
10 M 72 MCI
11 M 75 MCI
12 M 65 MCI
1 F 77 NL
2 F 76 NL
3 F 78 NL
4 F 66 NL
5 F 69 NL
6 F 74 NL
7 F 81 NL
8 F 75 NL
9 F 72 NL
10 F 66 NL
11 M 69 NL
12 M 76 NL
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mixture of florescent dextrans of increasing molecular
sizes (FITC-4 kDa, 10 mg/mL; Cascade Blue 10 kDa,
5 mg/mL; and rhodamine B isothiocyanate (RITC)-
70 kDa, 10 mg/mL) was added to the apical compartment.
Dextran permeability (luminal to abluminal flux) was
measured at 30 min following the addition of dextrans.
Apparent permeability coefficients (Pe; centimeters per
second) were calculated and expressed as percent control
[31]. For pharmacological inhibition (validation) studies,
cells were co-incubated with anti-HMGB1 antibody (gift
from Dr. Michael Bustin, NIH) or non-specific control
antibody for the indicated duration.
Immunofluorescence analysis
Immunocytochemistry (ICH) for zona occludin-1
(ZO-1) was performed using primary anti-ZO-1 anti-
body (Zymed Laboratories, San Francisco, CA), Alexa
Fluor 488-conjugated secondary antibody and 4,6-dia-
midino-2-phenylindole (DAPI; Molecular Probes, Eu-
gene, OR) as described in [32].
Statistical analysis
Data were expressed as mean ± SEM or SD. Data were
analyzed by one-way analysis of variance (ANOVA)
followed by Dunnett’s or Tukey’s post hoc multiple
comparison tests using GraphPad Prism Software Inc.
(La Jolla, CA, USA). P value was set to less than 0.05 for
statistical significance.
Results
Serum profile of proinflammatory “damage-associated”
factors in AD, MCI, and age-matched normal subjects
Part of the criteria for AD and MCI due to AD infers
that other more likely diagnoses are less likely than AD.
Although it does not totally eliminate, it clearly should
limit contamination by other diagnoses such as vascular
dementia, Parkinson’s disease with dementia, and pri-
mary systemic inflammatory diseases.
Levels of various proinflammatory markers including
Aβ, sRAGE, HMGB1, and S100β in serum samples de-
rived from control subjects (NL), AD, or MCI patients
(see Table 1 for demographic information) were mea-
sured by ELISA. As shown in Fig. 1, Aβ levels were
significantly higher in AD patients when compared to
MCI and NL. No statistically significant differences were
noted between MCI and NL groups. An unprecedented
pathophysiological parallelism between Aβ and sRAGE
(the soluble, circulating form of RAGE) [34, 35] levels
was also noted, as sRAGE was equally increased in the
plasma of AD patients vs. MCI and controls (Fig. 1). In
contrast, parallel measurements of HMGB1 in the MCI
cohort was significantly higher than the levels measured
in AD and control subjects. A side-by-side comparison
between AD and NL revealed a higher trend for HMGB1
levels in AD patients although the results were not sta-
tistically significant. No significant differences between
the three groups were observed with respect to S100β
levels.
The critical message from these results is that these pro-
inflammatory damage-associated molecules [28] (with the
exception of s100β) show specific patterns of expression
in relationship to the continuum from normal aging→M-
CI→AD. This strongly suggests that HMGB1 and/or
sRAGE in addition to Aβ could have a potential use as
prognostic/diagnostic markers for AD and MCI.
Serum expression/activity of soluble thrombomodulin in
AD, MCI, and control subjects
Additionally, in our efforts to develop a validated, non-
invasive biomarker for BBB EC damage in AD, we
measured both sTM antigen (TM-Ag) and TM activity
(TMa; which converts protein C to activated PC; see
“Methods” section). As shown in Fig. 2, we found signifi-
cant increase in TMa above age-matched controls when
MCI and AD levels were grouped (upper panel). We also
observed that MCI levels were, in fact, statistically
higher than those measured in AD patients (middle
panel). However, as shown in Fig. 2 (bottom panel), the
following relationship was found for TM Ag: AD>MCI>-
control (lower panel) with a significant increase in AD
vs. control subjects. Similar to remitting relapsing mul-
tiple sclerosis (RRMS) patients [36], increased levels of
sTM occur in sera of AD and MCI patients as compared
with controls (Fig. 2).
Effects of proinflammatory HMGB1 and thrombin on BBB
permeability in vitro
To directly assess microvascular damage associated with
elevated levels of these proinflammatory DAMPs in AD
and MCI patients, we next determined whether HMGB1
and/or the proinflammatory coagulation protease, throm-
bin, players in vascular barrier dysfunction in other tissues
could disrupt BBB integrity. As shown in Fig. 3a, one-way
ANOVA revealed that pre-treatment with recombinant
human HMGB1 (10 ng/mL) protein for 3 or 6 h signifi-
cantly increased BBB apical to basal permeability to FITC
dextran across the HBMEC monolayers (p < 0.001 vs. con-
trol). We also observed that the magnitude of dextran flux
was more pronounced with the duration of exposure to
HMGB1 (p < 0.01, 6 vs. 3 h; see inset in Fig. 3a). Import-
antly, HMGB1-induced increase in BBB paracellular dex-
tran permeability could be significantly and specifically
blocked by neutralizing antibody against HMGB1 [37],
whereas control (pre-immune) antibody failed to suppress
HMGB-1-induced BBB disruption at either incubation
time (Fig. 3a). Intriguingly, our preliminary data also indi-
cated that a specific fragment of rTM, called TM-D1, the
C-type lectin-like domain [38], can effectively block
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rHMGB1 activity, thus protecting the BBB against this
DAMP (data not shown).
Similarly, when we tested the effects of thrombin on BBB
integrity, we observed a significant and concentration-
dependent increase in FITC-dextran permeability across
the HBMEC monolayers (Fig. 3b). For instance, higher
thrombin concentrations (5 nM) more potently induced
BBB disruption (p < 0.0001 vs. control) when compared to
dextran permeability resulting from exposure to 0.5 or
1 nM (p < 0.001). However, we did not observe a further
elevation in thrombin-induced BBB dextran flux with lon-
ger exposure time (3 vs. 6 h), suggesting a maximum and
sustained response following 3 h of exposure. The negative
impact of HMGB1 and thrombin on BBB integrity is
further confirmed by corresponding immunostaining of
HBMECs that demonstrated a significant downregulation
of ZO-1 expression at intercellular tight junctions (TJs)
(Fig. 3c).
We next determined the extent of BBB disruption
following exposure to HMGB1 by assessing the perme-
ability to florescent dextrans of increasing molecular
sizes (4–70 kDa) across the hCMEC/D3 monolayers (see
“Methods” section). As shown in Fig. 4, HMGB1 expos-
ure for 3 h significantly and dose-dependently increased
the luminal to abluminal flux of all labeled dextrans
across the hCMEC/D3 monolayers in a size-selective
manner. The main effect of the treatment on 4-, 10-,
and 70-kDa dextran permeability was significant, as
indicated by one-way ANOVA. Further analyses by post
hoc tests revealed that high concentrations of HMGB1
Fig. 1 Serum profiling of clinical biomarkers of neuroinflammation to predict the conversion (continuum) of MCI to AD. a The serum levels of Aβ,
HMGB1, sRAGE, and s100β are shown individually for each subject belonging to age-matched control (NL), MCI, or AD cohorts to facilitate the
correlation of these markers. b Serum levels of each DAMP expressed as mean (±SD) for each cohort. *p < 0.05 and ***p < 0.01. n.s. not significant
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(10 and 50 ng/mL) significantly increased apical to basal
permeability of each dextran by 2.0–2.5-fold, as compared
to aged control group (p < 0.05 and p < 0.05, respectively;
Fig. 4). Although, HMGB1 at low concentration (5 ng/
mL) showed a marked increase in BBB permeability to all
dextrans, this effect was non-significant. In addition, we
observed a ceiling effect on BBB permeability to 10 and
70 kDa dextrans at HMGB1 (10 ng/ml; Fig. 4), as further
increase in concentration to 50 ng/mL did not elevate the
permeability to these dextrans.
Discussion
Although rigorous methods are used by the KU ADC to
enroll subjects in AD, MCI, MCI due to AD and normal
cohorts, one can never fully eliminate other systemic ill-
nesses that escaped notice. Such recruitment methods
are part of the approach that our colleagues at the KU
ADC take, quite similar to methods taken at other insti-
tutional ADCs. In this regard, our current results indi-
cate that three potent proinflammatory and damage/
danger-associated macromolecules are elevated in MCI
and AD sera: Aβ, sRAGE, and HMGB1. They further
suggest that one or more may herald the conversion of
MCI to AD (Fig. 1). Furthermore, our BBB in vitro data
show that one of these, HMGB1, along with the proin-
flammatory coagulation protease, thrombin, are proxim-
ate mediators of BBB dysfunction. With our present
results, we conclude that HMGB1 might be a better clin-
ical biomarker, along with sRAGE and Aβ, to predict the
course of neurodegeneration in AD subjects. In contrast,
although it also activates RAGE [39], from our results,
S100B does not appear to have applicability as a diag-
nostic or prognostic marker of neurodegeneration in
MCI and AD patients.
Considerable evidence indicates that blood levels of
sTM and von Willebrand factor (vWf) can serve as
surrogate biomarkers for diffuse microvascular damage
[39]. We had previously found that sTM plasma levels
were higher in RRMS patients than in patients with
systemic lupus erythematosus with diffuse microvascular
inflammation, indicating its potential utility as a bio-
marker for BBB damage [36]. Relevant to our current
results, others had suggested that sTM, along with vWf,
might be a good biomarker for AD-related microvascu-
lar damage [40]. In our present studies, soluble forms of
the anticoagulant/anti-inflammatory TM [38, 41] might
also serve as a biomarker for microvascular damage of
the BBB in AD. This is strongly suggested by the pattern
of expression for the sTM antigen which progressively
increases from controls to ↑MCI to ↑AD although only
the difference between control and AD was statistically
significant at this stage. Perhaps future studies involving
a larger cohort of patients will be able to provide add-
itional statistical power to the analysis. When data were
Fig. 2 Soluble thrombomodulin activity (TMa) and expression (TM-Ag)
in AD, MCI, and control subject sera. TMa and TM-Ag were assayed by
kits as described in the “Methods” section. Top panel represents the
combined TMa in MCI and AD patients above age-matched controls.
Middle panel shows the differences in TMa between MCI and AD
patients. Bottom panel represents the serum levels of TM-Ag in control,
MCI, and AD subjects. Data were expressed as mean ± SEM and *p< 0.05
Festoff et al. Journal of Neuroinflammation  (2016) 13:194 Page 6 of 12
Fig. 4 HMGB1 increases BBB permeability to dextrans of various sizes. HCMEC/D3 cells in the transwells were incubated with HMGB1 (5, 10, or
50 ng/ml) for 3 h and the apical to basal flux of a mixture of florescent-labeled dextrans of different sizes (FITC-4 kDa; Cascade Blue 10 kDa; and
RITC-70 kDa) was assayed following 30 min after the addition of dextrans. (*p < 0.05 vs. control and N = 5/condition)
Fig. 3 HMGB1 and thrombin impair BBB integrity. HBMEC monolayers were incubated with HMGB1 (10 ng/ml) and thrombin (Thr, 0.5, 1, or 5 nM)
for 3 or 6 h, and BBB integrity was assessed by paracellular permeability to FITC-dextran. a HMGB1 increases luminal to abluminal dextran flux
across HBMECs that was reversed by anti-HMGB1 antibody (HMGB1 Ab, 10 ng/ml). The time-dependent increase in HMGB1-induced BBB permeability
was shown in the inset. b Exposure to thrombin (3 or 6 h) dose-dependently increases BBB permeability to dextran in HBMECs. c HMGB1 and
thrombin disrupt ZO-1 linearity at cell-cell junctions. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. control; ●●●p < 0.01 vs. HMGB1 or HMGB1 + control
Ab. N = 5/condition
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aggregated, TMa was greater in disease (MCI + AD) than
aged-matched controls (see Fig. 2).
As with other vascular barriers [17, 18], human alpha
thrombin significantly compromised BBB integrity in
vitro at nanomolar concentrations (Fig. 3b), orders of
magnitude less than the circulating prothrombin levels
in the blood [38]. In an attempt to explain the throm-
bin’s effect on brain edema, Guan and colleagues
injected thrombin stereotactically into the rat caudate
nuclei and found a marked extravasation of Evans Blue
dye, suggesting BBB disruption [42]. These authors also
demonstrated that exposure to thrombin upregulated
the endothelial expression of matrix metalloproteinase-
2 possibly through the activation of protease-activated
receptor 1 (PAR1). In similar direct experiments using
different vascular barrier models, Garcia’s group and
others showed that thrombin mediated barrier disrup-
tion, indeed, via a PAR1 mechanism [17, 18, 43]. Al-
though, we have no current direct evidence that PAR1
mediated the BBB disruption effects of thrombin, the
nanomolar concentrations are in agreement with medi-
ation via PAR1. However, our preliminary experiments
suggested that the BBB disruptive effects of thrombin
are a direct measure of its proteolytic activity, since
recombinant hirudin, a specific thrombin inhibitor,
inhibited the effects of thrombin (data not shown). Fur-
ther indicating thrombin was likely interacting with a
protease-activated receptor (PAR) on the EC surface, an
rTM fragment that binds both thrombin and PC
(TMD23) also blocked thrombin’s effects on BBB per-
meability (not shown).
The proinflammatory DAMP, HMGB1, dramatically
enhanced BBB permeability to various molecular weight
dextrans in primary HBMEC or hCMEC/D3 cultures,
following incubation for 3 or 6 h. These BBB changes in-
cluding the significant downregulation of ZO-1 expres-
sion at intercellular (TJs) clearly mirror what has been
observed in vivo in animal studies that suggest the pres-
ence of amyloid beta is a factor in the “breach” of the
BBB [44]. In experimental animals and cell cultures, beta
amyloid proteins induce matrix metalloproteinase-9
(MMP-9) [45]. Transgenic mutant mice with mutant hu-
man amyloid protein show disruption of the BBB [46].
Furthermore, transgenic mice with apoE4 demonstrate
BBB breakdown by activating the proinflammatory
cyclophilin A-MMP-9 pathway in the brain pericytes,
which, in turn, results in degradation of the BBB TJs and
basal lamina (BL) proteins [47]. Mice overexpressing
Aβ-precursor protein have pericyte loss, elevated brain
Aβ40 and Aβ42 levels accelerating amyloid angiopathy,
and cerebral amyloidosis [48].
Others have also shown that BBB dysfunction in rats,
whether due to experimental stroke or traumatic brain
injury (TBI), can be prevented by a neutralizing antibody
to HMGB1 [49, 50]. Outside the cell, oxidized HMGB1
is known to ligate three different pattern recognition
receptors all expressed on the surface of these ECs (as
illustrated in Fig. 5). These include TLR2, TLR4, and
RAGE [51, 52], and each can bind other ligands, such as
Aβ, contributing to vascular complications of other dis-
eases [53]. Both TLR and RAGE signaling leads to down-
stream NFkB activation with subsequent increase in the
expression/release of tumor necrosis factor (TNF), thus
ensuring that the inflammatory signal is maintained and
amplified [54].
Over the last 15 years, the concept that the BBB might
function both as source and target of proinflammatory
factors is supported by numerous studies showing that
the cerebral microcirculation is in an “activated proin-
flammatory” stage in neurodegenerative diseases such as
AD [15, 55] and is a target for various proinflammatory
factors. PAUSE Circulating Aβ is a proinflammatory
cytokine-induced DAMP that binds to RAGE and TLR2
[56]. Like S100β and HMGB1, Aβ can exacerbate proin-
flammatory cytokine production such as TNF and
interleukin-1 beta (IL-1β); however, in innate immunity,
TNF dominates. When HMGB1 binds to RAGE and/or
TLRs on microvascular ECs, it releases TNF and other
cytokines [37], making the BBB also a source of these
proinflammatory factors, and the axis in AD has
attracted considerable attention [56]. Soluble RAGE or
sRAGE, sometimes referred to as endogenous secretory
RAGE, which can be produced either by splicing or pro-
teolytic shedding, appears to play the role of a “decoy”
to tie up RAGE ligands, such as S100/calgranulin family
members, HMGB1, or Aβ [39]. The S100B/RAGE axis
has been of considerable interest in AD, but earlier re-
ports suggested that lower sRAGE levels characterized
AD [39]. Interestingly, we found significant correlation
between Aβ and HMGB1 or sRAGE (Fig. 1). Further-
more, the levels of HMGB1 in serum were in the range
of rHMGB1 used in the BBB permeability experiments
(Figs. 3a and 4), suggesting a continuum from normal
through MCI to AD may exist. We did not find an indi-
cation that S100B might be useful, although a trend of
significance in the MCI due to AD cohort was found
(Fig. 1).
Just in the last decade, it has become increasingly ap-
preciated that inflammation and coagulation are linked
evolutionary defense systems [41], a fact that is slowly
becoming recognized in the CNS as well. TBI and ische-
mic and hemorrhagic stroke are all characterized by
increased levels of intraparenchymal thrombin and
HMGB1 as well as evidence of BBB dysfunction [42, 49,
50]. In the brain, low concentrations of thrombin act
through its principal receptor, PAR1, to induce neuro-
protection [57]. In contrast, at higher concentrations,
thrombin causes brain damage [58], where we showed
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that it appears to act via PAR4 [59–61]. Through PAR
activation, thrombin directly affects the activity of mul-
tiple cell types and regulates a variety of biological func-
tions, including inflammation, leukocyte migration, and
vascular permeability [61]. Relevant to this and our
current results, all PARs are expressed in microvascular
ECs [62], and PAR1, at least, is expressed in ECs of the
BBB [63].
Also attesting to evolutionary linkage, direct relation-
ships also exist between thrombin and HMGB1. HMGB1
is involved in a number of systemic vascular diseases
[64], is increased in stroke [65], and found around amyloid
plaques and NFTs in AD brains [66], where thrombin and
prothrombin accumulate as well [67]. Both HMGB1 and
thrombin are released in various neurologic conditions,
and HMGB1 promotes coagulation [68]. Taken together,
these observations raise the possibility that HMGB1 and
thrombin also participate during innate immune neuroin-
flammatory situations such as in AD and which contribute
to BBB dysfunction and WBC transendothelial migration.
Finally, we have envisioned our present data in corrob-
oration with previous findings schematically in Fig. 5.
This shows that increased levels of danger/damage-asso-
ciated, proinflammatory molecules (the alarmin DAMPs,
HMGB1 and S100B, as well as Aβ) feature prominently
in the AD continuum from normal aging through MCI
by acting on TLRs and RAGE to induce neuroinflamma-
tory signaling at the BBB endothelium. This results in
increased expression of the transcription factor NFkB
causing increased TNF and IL-1β (other interleukins),
ROS, and adhesion molecules along with degradation of
tight junction (TJ) proteins such as ZO-1. Both endogen-
ous as well as exogenous means exist to combat this im-
balance including the proteolytic release of sRAGE and
sTM, both of which selectively bind up HMGB1 (possibly
other alarmins) preventing engagement of RAGE or TLRs.
This also allows for the development of novel therapeutic
targets that act like sRAGE and sTM, in a manner less
burdensome and potentially with fewer side effects than
by administering neutralizing antibodies to HMGB1, such
as recently used by others in rat models of stroke, TBI,
and Parkinson’s disease [49, 50, 69].
Conclusions
An increased understanding of the role of HMGB1 and
thrombin in BBB dysfunction as well as activation and
transendothelial migration of WBCs contributing to
neuroinflammation in AD may allow for the discovery of
novel therapeutic targets and treatment strategies. Not
only might these facilitate treatment to halt progression in
AD but these might also aid in means to detect the con-
version from MCI to pre-clinical AD, as well as in other
neurological disorders that display BBB dysfunction.
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